Compumedics Limited · ASX:CMP
Compumedics — Shareholder Meeting (October 2021)
26 slides from Compumedics's shareholder meeting presentation, Oct 28, 2021
Slide 1: Corporate presentation October 2021
Corporate presentation September 2016 For personal use only Cover sheet to be added – Simone Corporate Presentation October 2021 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain R
Slide 2: AGM Agenda
AGM Agenda For personal use only Meeting opens Chair’s address Ordinary business Meeting closes 2
Slide 3: Ordinary Business
Ordinary Business For personal use only Item 1 Financial Statements and Reports Item 2 Re-election of a Director – David Lawson Item 3 Adoption of Remuneration Report (non-binding resolution) 3
Slide 4: Who is Compumedics?
Who is Compumedics? For personal use only A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including long- Highly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain r
Slide 5: FY2021 – Performance Review
FY2021 – Performance Review For personal use only Revenue $35.7m, EBITDA $2.6m, NPAT $1.0m FY21 FY20 Variance Comment Revenues stabilised and resumed growth as Revenue $35.7m $35.1m 2% COVID-19 impacts lessened as FY21 progressed. Underlying profitability improved as sales EBITDA – increased and t
Slide 6: FY2021 – Performance Review
FY2021 – Performance Review For personal use only Core: Europe rebounded well in FY21 with revenues increasing 49% over the prior period, this was driven by revenue increases in France, Germany and the DWL business. Core: Increases in Europe were off-set by declines in the USA based business, do
Slide 7: Revenue Composition at $35.7m June 2021
Revenue Composition at $35.7m 30 June 2021 For personal use only By geographic region By product/market Customer Consumables Care 9% 10% Europe, USA, 29% 31% Brain - Sleep - Blood Flow Clinical Monitoring Diagnostics 21% 28% Sleep - Aust, 13% Brain - Nexus360 Research Asia, 27% 15% Brain - Clinical2
Slide 8: Revenue Bridge Chart – FY20 to FY21
Revenue Bridge Chart – FY20 to FY21 For personal use only 8
Slide 9: EBITDA Bridge Chart – FY20 to FY21
EBITDA Bridge Chart – FY20 to FY21 For personal use only 9
Slide 10: Core Business – COVID-19 impacts absorbed, profits continue
Core Business – COVID-19 impacts absorbed, profits continue For personal use only 10
Slide 11: Core Business – Consistent Net Cash Position
Core Business – Consistent Net Cash Position For personal use only $m FY16 FY17 FY18 FY19 FY20 FY21 Cash 3.1 4.1 3.9 4.6 6.4 6.8 Trade receivables 11.9 13.1 18.3 16.0 12.6 13.0 Inventories 6.5 7.4 7.6 7.8 8.8 9.7 Capitalised R&D 2.4 2.4 4.0 6.8 2.8 4.1 Tax asset 0.5 0.8 0.1 0.0 0.8 0.8 PP&E 0.8 0.7
Slide 12: China - We are the number one Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China For personal use only Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin China Sales (invoiced) – USD’s Beijing 88 23 2 Liaoning Ningxia Qinhuangdao QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 9.6 Gan
Slide 13: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out For personal use only Sales – schematic only FY19A FY20A FY21A FY22F FY23F FY24F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Instit
Slide 14: Core Business – Premium Focus
Core Business – Premium Focus For personal use only Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics
Slide 15: Core Business - Growth Drivers
Core Business - Growth Drivers For personal use only Compumedics/Neuroscan innovative brain analysis software and high-performance amplifiers are unrivalled world class technology. We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumed
Slide 16: Core Business: New products > New markets – Falcon HST
Core Business: New products > New markets Falcon HST For personal use only A new generation of home or professional user experience for the home sleep testing market. Compumedics regulatory phases have now advanced to enable market release activities for this new device Will fully integrate with
Slide 17: Falcon HST – market drivers
Core Business: New products > New markets Falcon HST – market drivers For personal use only The market opportunity (estimates to assist OSA sufferers) – USA 54m people, USD2.7b pa, Europe 66m people, USD 2.6b pa, Asia 77m, USD1.9b pa 26%1 of adults worldwide, including 54M in the US alone, suffe
Slide 18: Core Business: New products – Okti
Core Business: New products > New markets Okti For personal use only Best in class ambulatory, home or clinical EEG monitoring device, scalable from 32 channels up to 256 channels for routine EEG monitoring through to long-term epilepsy monitoring, including high density EEG capabilities Can be
Slide 19: Core Business: New Products – CURRY
Core Business: New Products > New Markets CURRY 9 For personal use only Compumedics class leading brain analysis software includes spike/seizure detection routines for the first time, incorporating artificial intelligence machine learning algorithms, enabling clinicians to quickly isolate epilepto
Slide 20: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out For personal use only Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Long term epilepsy Leverage existing TCD Leverage CURRY Next generation diagnostic platforms for market penetration
Slide 21: Step out - Brain Imaging
Step out 1 - Brain Imaging: For personal use only Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated FY22 – second and final FY19/FY20 CMP software is already the gold at about 20 systems a year at an phase of MEG has sold and standard for
Slide 22: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics For personal use only Nexus 360 Operational systems have been Compumedics is Key partners (professional developed for the cloud-based continuing to seek being pursued cloud sleep capture, transfer appropriate third include web, diagnostics) sold and tra
Slide 23: Directors & Executive Team
Directors & Executive Team Key Management For personal use only David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs Mr Tucson Dunn Mr. David Lawson Non Executive Director Chief Financial Officer CMP Tenure 12 months & Company Secretary CMP Tenure 20 yrs Mr. Warwick Freeman Kerry Hubic
Slide 24: Investor Summary
Investor Summary Core business profitable with on-going growth For personal use only opportunities in key global markets International sales force Compumedics remains expansion, neurology and sleep committed to continuing to market opportunity and earnings deliver superior returns to improvement ini
Slide 25: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability o
Slide 26: compumedics.com.au
For personal use only compumedics.com.au 26